Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Stock Is Skyrocketing Today

By Keith Speights - Updated Feb 1, 2021 at 1:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech had lots of good news.

What happened

They say that good things come in threes. That appears to be the case for Dynavax Technologies (DVAX -3.40%) today. Shares of the biotech were skyrocketing 47.1% as of 12:36 p.m. EST on Monday after the company announced three developments.

First, Dynavax and Clover Biopharmaceuticals announced plans to kick off a phase 2/3 clinical study in the first half of this year evaluating Clover's S-Trimer COVID-19 vaccine candidate with Dynavax's CpG 1018 adjuvant. Second, Dynavax and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a $99 million deal for Dynavax to supply CpG 1018 manufacturing for the global COVID-19 response. Third, the company announced that the U.K. government is ordering an additional 40 million doses of Valneva's COVID-19 vaccine VLA2001, which uses Dynavax's CpG 1018 adjuvant.

COVID-19 vaccine vials next to a syringe with a dollar sign in one of the vials

Image source: Getty Images.

So what

All three of these announcements are very good news for Dynavax. And they all served as solid catalysts for the biotech stock

Dynavax has committed to delivering enough CpG 1018 adjuvant for 100 million doses of VLA2001 in total. That will generate revenue for the company of up to $230 million this year. And Valneva has an option to buy additional quantities of Dynavax's adjuvant to support another 90 million doses of VLA2001. The U.K. government's order announced today makes it more likely that Valneva will need to obtain more adjuvant from Dynavax.

Turning to the CEPI deal, the nonprofit organization will fund up to $99 million to Dynavax for manufacturing CpG 1018. But this amount will technically be a loan. As Dynavax sells its adjuvant, it will reimburse CEPI for the funded manufacturing cost. But if the vaccine programs covered under the agreement don't pan out, the loan will be forgiven. Clover's S-Trimer is one of the COVID vaccine programs funded by CEPI.

Now what

Dynavax should have plenty of other potential catalysts throughout this year. One to watch especially that's related to today's announcements is Valneva's announcement of initial results from its phase 1/2 studies of VLA2001, expected in April.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
$10.80 (-3.40%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.